Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Celebrate with Us! Vaccine Rollouts Mark the Light at the End... March 8, 2021 Antibody Drug Ejects Problematic Proteins from Cancer Cells December 13, 2023 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 Load more HOT NEWS Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors John Cena Set The Record For Most Make-A-Wish Visits And He... FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC
